← Halozyme Therapeutics overview

Halozyme Therapeutics vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Halozyme Therapeutics Inc (HALO)

Q3 2026
▲3▼1

Halozyme Q3: Strong Earnings, New Deals, Legal Win, But Dilution Risk

  • Q2 Earnings Beat and Guidance Raise Halozyme reported Q2 revenue of $481 million, up 48% from a year earlier, and raised its full-year guidance. The stock hit a 52-week high as investors cheered the strong results and brighter outlook.

    This is the core financial performance that directly drove the stock higher during the quarter.

  • New ENHANZE Partnerships and Expanded Collaboration Halozyme signed new ENHANZE deals with Incyte, Vertex, and GSK, and expanded its existing collaboration with argenx. These agreements broaden future royalty streams, giving investors more confidence in long-term revenue growth.

    New partnerships are a key growth driver and were a major positive catalyst during the quarter.

  • Legal Win and Positive Trial Data A Dutch court blocked Merck’s subcutaneous Keytruda for patent infringement, potentially adding royalties or damages for Halozyme. Also, positive Darzalex Faspro trial data support long-term royalties, reinforcing the company’s intellectual property strength.

    These legal and clinical developments protect and enhance future revenue streams, directly impacting investor sentiment.

  • Convertible Notes Raise Creates Dilution Risk Halozyme raised $1.3 billion in convertible notes, strengthening its balance sheet but potentially diluting shares if the stock price rises above the conversion price. This is a risk that could weigh on the stock if not managed carefully.

    This is a significant counterweight to the positive news, as dilution can pressure the stock price.

September 2026
▲3

Halozyme's Royalty Engine Roars as Legal Wins and Deals Pile Up

  • Q2 Beat and Raised Guidance Halozyme's Q2 revenue jumped 48% to $481 million, beating estimates, and the company raised full-year guidance. This shows its royalty business is growing faster than expected, which directly boosts investor confidence and the stock price.

    This is the core fundamental driver of the stock's recent surge and answers why HALO is moving.

  • New ENHANZE Deals Expand Royalty Stream Halozyme signed five new collaborations, including with Vertex, GSK, and Incyte, and expanded its argenx deal from six to eight targets. More partners mean more future milestone payments and royalties, which supports long-term revenue growth and lifts the stock.

    New deals are a key growth catalyst that directly increases future royalty revenue.

  • Dutch Court Blocks Merck's Keytruda SC A Dutch court ruled that Merck's subcutaneous Keytruda infringes Halozyme's patent, banning sales in eight European markets. This legal win protects Halozyme's technology and could lead to royalties or damages from Merck, boosting the stock.

    This is a major legal victory that validates Halozyme's patent portfolio and could unlock significant value.

  • Upsized Convertible Notes Offering Halozyme raised $1.3 billion in convertible notes to refinance older debt. While this strengthens the balance sheet and funds growth, it also creates potential future dilution if the stock rises above the conversion price, which can weigh on shares.

    This financing event affects the capital structure and has both positive and negative implications for the stock.

Latest
▲3

Halozyme's Royalty Engine Roars as Legal Wins and Deals Pile Up

  • Q2 Beat and Raised Guidance Halozyme's Q2 revenue jumped 48% to $481 million, beating estimates, and the company raised full-year guidance. This shows its royalty business is growing faster than expected, which directly boosts investor confidence and the stock price.

    This is the core fundamental driver of the stock's recent surge and answers why HALO is moving.

  • New ENHANZE Deals Expand Royalty Stream Halozyme signed five new collaborations, including with Vertex, GSK, and Incyte, and expanded its argenx deal from six to eight targets. More partners mean more future milestone payments and royalties, which supports long-term revenue growth and lifts the stock.

    New deals are a key growth catalyst that directly increases future royalty revenue.

  • Dutch Court Blocks Merck's Keytruda SC A Dutch court ruled that Merck's subcutaneous Keytruda infringes Halozyme's patent, banning sales in eight European markets. This legal win protects Halozyme's technology and could lead to royalties or damages from Merck, boosting the stock.

    This is a major legal victory that validates Halozyme's patent portfolio and could unlock significant value.

  • Upsized Convertible Notes Offering Halozyme raised $1.3 billion in convertible notes to refinance older debt. While this strengthens the balance sheet and funds growth, it also creates potential future dilution if the stock rises above the conversion price, which can weigh on shares.

    This financing event affects the capital structure and has both positive and negative implications for the stock.

July 2026
▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

  • Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.

    This is the biggest new financial event, directly boosting investor confidence and the stock price.

  • New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.

    This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.

  • Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.

    It reinforces demand for an existing partnered product, which drives recurring royalty revenue.

  • Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.

    This captures the market's positive reaction and momentum, which can attract more investors.

▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

  • Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.

    This is the biggest new financial event, directly boosting investor confidence and the stock price.

  • New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.

    This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.

  • Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.

    It reinforces demand for an existing partnered product, which drives recurring royalty revenue.

  • Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.

    This captures the market's positive reaction and momentum, which can attract more investors.

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲2▼2

Regeneron's Q3: pipeline wins, Sanofi deal, but melanoma setback

  • Strong Q2 results and pipeline progress Regeneron reported Q2 revenue up 17% to $4.29 billion, received FDA priority review for cemdisiran in myasthenia gravis, and won approval for Pasatru in FOP disease. These advances support future growth.

    These positive developments drove investor optimism and supported the stock.

  • Expanded Sanofi deal and obesity drug data Regeneron expanded its Sanofi partnership with $1 billion upfront and four pipeline therapies. Its obesity drug trevogrumab preserved about 70% of muscle loss in a Phase 2 trial, showing promise in a large market.

    The deal and trial data are new positive catalysts for Regeneron's growth outlook.

  • Failed melanoma trial and lawsuits A failed melanoma trial led to class-action lawsuits and an $11 billion market-value loss. This setback raised concerns about pipeline execution and weighed on the stock.

    This was a major negative event that hurt investor confidence and the share price.

  • Eylea competition and Sanofi deal disappointment Eylea faces biosimilar and competitive threats, notably Kodiak's less-frequent-dosing eye drug. The Sanofi deal left Dupixent profit-sharing unchanged, disappointing some investors and briefly pressuring shares.

    These competitive and deal-related concerns created headwinds for the stock.

August 2026
▲2▼1

Regeneron's strong Q2 and pipeline wins offset by legal and competitive risks

  • Strong Q2 earnings and margin improvement Regeneron beat Q2 estimates with revenue up 17% to $4.29 billion, driven by Dupixent and high-dose Eylea. Repaying the Sanofi Development Balance should improve margins, and buybacks and dividends support shareholder value.

    This point explains the positive financial performance that drove the stock during the period.

  • Pipeline progress and new Sanofi deal FDA approval of Pasatru for rare FOP disease validates Regeneron's drug platform. A new Sanofi deal adds $1 billion upfront and four pipeline therapies, strengthening the pipeline and providing external validation.

    This point highlights key pipeline and partnership developments that boosted investor sentiment.

  • Pipeline uncertainty and Eylea competition Mixed melanoma trial results and increasing competition for Eylea add pipeline uncertainty. These factors offset strong commercial performance and contribute to a balanced but cautious outlook.

    This point explains the competitive and pipeline challenges that acted as a counterweight to positive developments.

Latest
▲2▼2

Regeneron's Sanofi deal and pipeline progress offset by Eylea competition and lawsuits

  • Sanofi deal expands pipeline with $1B upfront Regeneron and Sanofi agreed to jointly develop four long-acting immunology therapies, led by REGN20423, in a deal worth up to $8 billion including $1 billion upfront. This brings cash and pipeline growth, supporting future revenue and the stock.

    This is a major new partnership that directly boosts Regeneron's pipeline and cash, a key positive driver.

  • Securities class action lawsuits weigh on sentiment Multiple law firms filed class actions alleging Regeneron made false statements about its Fianlimab-Libtayo trial, causing investor losses. The legal uncertainty and potential reputational damage pressure the stock, though the company denies wrongdoing.

    These lawsuits are a new negative overhang that could affect investor confidence and lead to financial penalties.

  • Mixed melanoma trial results lead to pullback Regeneron's melanoma drug trial produced mixed results, causing shares to give back some gains. This setback raises doubts about the drug's potential and adds to pipeline uncertainty, weighing on the stock.

    This is a new clinical setback that directly impacts Regeneron's oncology pipeline and investor expectations.

  • Buybacks and dividend support shareholder value Regeneron confirmed its quarterly dividend, updated on share repurchases, and reported Q2 results. With the stock trading below fair value estimates, these capital returns and pipeline progress support the shares.

    This shows management's commitment to returning cash and the stock's valuation appeal, a positive for investors.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.